Watch for Ibsrela for Irritable Bowel Syndrome
June 2022
New Rx Ibsrela (tenapanor) will soon hit shelves for irritable bowel syndrome with constipation (IBS-C) in adults.
You’ll hear that Ibsrela is the first “NHE3 (sodium/hydrogen exchanger 3) inhibitor” for IBS-C.
It’s touted to have a “triple action” that blocks dietary sodium absorption...improves leaky gut...and reduces visceral hypersensitivity, or pain-sensing nerve activity in the GI tract.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote